StreetInsider.com News Articles

Akebia doses first patient in Phase 2 kidney disease trial

Mon, 14 Sep 2026 08:02:44 -0400

Akebia Therapeutics (Nasdaq: AKBA) announced that the first patient has been dosed in a Phase 2 basket trial evaluating ebribafusp, an investigational anti-C3d factor H fusion protein, for the treatment of rare complement-mediated kidney diseases.

The open-label trial is studying ebribafusp across three conditions: IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial is expected to enroll up to 30 patients, who will receive once-weekly subcutaneous doses for 26 weeks, followed by a long-term extension study for responders. Initial data is expected in 2027.

The trial's primary endpoint is the incidence of adverse events. Secondary endpoints include changes in proteinuria measured by

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Mon, 14 Sep 2026 08:00:00 -0400

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy

Initial data is expected in 2027

WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy (IgAN), lupus nephritis (LN), and C3 glomerulopathy (C3G). Ebribafusp

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Mon, 14 Sep 2026 08:00:00 -0400

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy

Initial data is expected in 2027

WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy

Tue, 08 Sep 2026 08:40:19 -0400

WestPark Capital initiates coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $4.50.

For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.

Shares of Akebia Therapeutics closed at $0.97 yesterday.

Form 4 Akebia Therapeutics, For: Aug 06 Filed by: Butler John P.

Mon, 10 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260810/26897903.html

Form 4 Akebia Therapeutics, For: Aug 06 Filed by: Butler John P.

Mon, 10 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260810/26897903.html

Leerink Downgrades Akebia Therapeutics (AKBA) to Market Perform

Fri, 07 Aug 2026 06:11:45 -0400

Leerink analyst Roanna Ruiz downgraded Akebia Therapeutics (NASDAQ: AKBA) from Outperform to Market Perform with a price target of $1.00.

For an analyst ratings summary and ratings history on Akebia Therapeutics click here. For more ratings news on Akebia Therapeutics click here.

Shares of Akebia Therapeutics closed at $0.95 yesterday.

H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Thu, 06 Aug 2026 06:58:55 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $6.00 price target on Akebia Therapeutics (NASDAQ: AKBA).

The analyst commented: "We view AKBA’s near-term strategy as being two-fold: (1) execute commercial efforts for oral tablet VAFSEO (vadadustat) for chronic kidney disease (CKD) anemia patients on dialysis; and (2) advance the kidney disease pipeline discussed below, which we view as offering upside beyond the VAFSEO and AURYXIA commercial contributions. Most importantly, we believe continued VAFSEO uptake by dialysis organizations (DOs) can be driven by the positive interim analysis from the VOICE trial demonstrating improved safety outcomes for CKD patients treated with

Akebia Therapeutics (AKBA) Tops Q2 EPS by 1c

Wed, 05 Aug 2026 17:10:40 -0400

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $49 million versus the consensus estimate of $50.93 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

Form S-8 Akebia Therapeutics,

Wed, 05 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260805/26875561.html

Form S-8 Akebia Therapeutics,

Wed, 05 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260805/26875561.html

Form 10-Q Akebia Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874343.html

Form 10-Q Akebia Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874343.html

Form 8-K Akebia Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874232.html

Form 8-K Akebia Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874232.html

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Wed, 05 Aug 2026 16:05:00 -0400